FOLD

STRUCTURAL ANALYST NOTE: FOLD (Amicus Therapeutics, Inc.) Date: 2026-06-13 Current Price: $14.49

1. Structural Readiness

Conservative Entry: Not yet defined (awaiting breakout confirmation) Aggressive/Pre-Breakout Entry: $14.49 (Current Price) Breakout Level: Pending Extension: — Pivot Strength: —

Analysis:

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Thesis: None named at this date.

Analysis: As of 2026-06-13, FOLD is not anchored to a named macro or secular thesis in the current context. The investment case is strictly tactical, driven by the quality of the structural setup and the immediate business fundamentals. The conviction must be derived entirely from the setup quality (the forming coil) and the strength of the underlying business metrics, rather than a broader thematic tailwind. No external macro drivers are currently assigned to this name.

3. Business Fundamentals

Company Overview: Amicus Therapeutics, Inc. operates in the Healthcare sector, specifically within the rare disease and precision medicine industry. The company develops and commercializes therapies for rare genetic diseases.

Business Model & Operations: The company generates revenue through the commercialization of approved therapies and is advancing a pipeline of investigational treatments.

• Primary Commercial Offering: Galafold, an orally administered precision medicine for adult patients with Fabry disease (specifically those with amenable galactosidase alpha gene variants).
• Secondary Offerings: Pombiliti and Opfolda, which have shown significant growth.
• Pipeline: Includes DMX-200 (Phase III for FSGS), AT-GAA (Pompe disease), and AT-GTX-502 (AAV gene therapy for CLN3).

Supporting Evidence (as of 2026-06-13):

• Commercial Growth: In the third quarter of 2025 (reported Nov 4, 2025), Galafold delivered 13% year-over-year patient growth. Third-quarter revenue reached $30.7 million, up 42% at constant exchange rates. Year-to-date, Pombiliti and Opfolda grew 59% at CER.
• Market Position: Management stated Galafold is "clearly positioned as the treatment of choice for amenable patients," with literature suggesting actual prevalence may exceed 100,000 patients, indicating a substantial undiagnosed population.
• Pipeline Progress: The ACTION3 pivotal study for DMX-200 was over 90% enrolled as of late 2025 and remained on track to complete enrollment by the end of that year.
• Financial Outlook: Management reaffirmed confidence that combined sales of their two commercial products (Galafold and the others) are on track to deliver $1 billion in 2028.
• Financial Spine: Forward consensus EPS for FY1 is 0.35667, and FY2 is 0.64.

4. Archetype and Conviction

Archetype: Margin Inflector Rationale: The name fits the "Margin Inflector" archetype because the company is transitioning from a high-growth, pre-profitability phase to a stage where commercial scale (Galafold, Pombiliti, Opfolda) is driving revenue expansion ($30.7M in Q3 2025, 42% growth) while management guides toward a $1 billion combined sales run-rate by 2028. The "inflection" is the scaling of commercial operations to support the pipeline (ACTION3, DMX-200) and the potential for operating leverage as fixed R&D costs are spread over a larger revenue base.

Valuation & Conviction Stack:

• Thesis Strength: Moderate. The thesis is tactical and relies on the execution of the commercial ramp and the successful completion of the ACTION3 study.
• Evidence Quality: High. The evidence base is robust, citing specific earnings transcripts (Nov 2025) and company profiles (June 2026) with concrete figures (13% patient growth, $30.7M revenue, 90% enrollment).
• Structural Quality: Low to Moderate. The ATR is sub-threshold (0.1%), and the setup is "forming" rather than "confirmed." The lack of a breakout signal limits the structural quality score.
• Setup Readiness: Partial. The price is holding, but the breakout has not fired.
• Rerating Potential: Dependent on the confirmation of the $1 billion sales target and the successful completion of the ACTION3 study.

5. Invalidations, Strengths, and Gaps

What Would Invalidate:

• Significant delays or failures in the ACTION3 pivotal study enrollment or results.
• A material deviation from the $1 billion 2028 sales guidance.

What Would Strengthen:

• Positive top-line data from the ACTION3 study prior to the end of the year.
• Further acceleration in Galafold patient starts beyond the 13% YoY growth rate.

Gaps in Evidence:

• Current Volatility: The ATR of 0.1% is extremely low, suggesting a lack of market participation or a "dead" setup that requires a catalyst to move.
• 2026 Specifics: While 2025 data is robust, specific 2026 financial results or updated guidance for the current year (2026) are not explicitly detailed in the provided evidence beyond the consensus EPS estimates.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Galafold delivered 13% YoY patient growth and Q3 revenue of $30.7M; ACTION3 study is 90% enrolled and on track; consensus EPS shows positive trajectory (FY1: 0.36, FY2: 0.64). Key risks: Sub-threshold ATR (0.1%) indicates low volatility and potential lack of momentum; setup is forming but not confirmed; reliance on future clinical data for DMX-200. Sizing hint: Position size should be conservative given the unconfirmed structural breakout and low volatility environment. Expected path: Management expects combined commercial sales to reach $1B by 2028; structural implication is a potential breakout if price holds above support and volatility expands. Expected horizon: 3 to 6 months for structural confirmation or invalidation.